宏源药业 (301246)
Hubei Hongyuan Pharmaceutical Technology Co.,Ltd.
K-Line Chart
No K-line data available
Company NameHubei Hongyuan Pharmaceutical Technology Co., Ltd.
Listing Date2023-03-20
Issue Price50RMB
Registered Capital40000.6810k RMB
Legal RepresentativeYin Guoping
Registered AddressNo. 8 Hongyuan Road, Economic Development Zone, Fengshan Town, Luotian County, Hubei Province
IndustryChemical Pharmaceuticals
Main BusinessResearch, development, production, and sales of organic chemical raw materials, pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and pharmaceutical preparations.
Company ProfileHubei Hongyuan Pharmaceutical Technology Co., Ltd. is a high-tech enterprise integrating the R&D, production, and sales of organic chemical raw materials, pharmaceutical intermediates, APIs, and pharmaceutical preparations. The company has established a relatively comprehensive pharmaceutical industry chain, achieving full product route coverage for nitroimidazole antibacterial drugs and anti-herpes virus drugs from starting materials and key intermediates to APIs. It has become one of the world's major suppliers of nitroimidazole antibacterial APIs and intermediates, anti-herpes virus APIs and intermediates, and penicillin antibacterial drug intermediates.
The company possesses multiple proprietary intellectual property rights and technologies in APIs, pharmaceutical intermediates, basic chemical raw materials, and pharmaceutical preparations, holding 62 patents, including 48 invention patents, 8 utility model patents, and 6 design patents. The company has passed certifications such as GMP, ISO9001, and ISO14001, and completed registrations including CEP and REACH. It has obtained 44 drug approval numbers, 6 API filing numbers, 2 veterinary drug product approval numbers, 1 domestic food registration number, and 1 feed additive product approval number.
Stock Details
1. Key Indicators
- Total Shares(W): 40000.68
- Circulating A-Shares(W): 16004.28
- Earnings Per Share(RMB): -0.0028
- Net Assets Per Share(RMB): 10.8384
- Operating Revenue(W RMB): 131707.61
- Total Profit(W RMB): 519.63
- Net Profit Attributable to Parent(W RMB): -110.02
- Net Profit Growth Rate(%): -103.04
- Weighted Return on Equity(%): -0.0300
- Operating Cash Flow Per Share(RMB): -0.4640
- Undistributed Profit Per Share(RMB): 4.0355
- Capital Reserve Per Share(RMB): 5.4310
2. Main Business
The main business covers:
- R&D, production, and sales of organic chemical raw materials
- R&D, production, and sales of pharmaceutical intermediates
- R&D, production, and sales of active pharmaceutical ingredients (APIs)
- R&D, production, and sales of new energy and pharmaceutical preparations
3. Company Basic Information
- Company Name: Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
- Listing Date: 2023-03-20
- Industry: Pharmaceutical Manufacturing
- Address: No. 8 Hongyuan Road, Economic Development Zone, Fengshan Town, Luotian County, Hubei Province, China
- Website: www.hbhypharm.com
- Company Profile: The company was formerly known as Hongyuan Co., Ltd. It was approved to change to a joint-stock company at a shareholders' meeting on February 24, 2014, and completed its industrial and commercial registration on April 8, 2014. The company is primarily engaged in the R&D, production, and sales of organic chemical raw materials, pharmaceutical intermediates, APIs, new energy, and pharmaceutical preparations.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Zhejiang Aobei Investment Management Co., Ltd. | General Legal Person | 200.61 | 1.25 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 110.09 | 0.69 |
| 3 | Jointown Pharmaceutical Group Co., Ltd. | General Legal Person | 105.00 | 0.66 |
5. Concept Sectors
- Lithium Battery
- Solid-State Battery
- Synthetic Biology
- Margin Trading & Securities Lending
- Active Stock
- High P/E Ratio
- High Turnover
- Below IPO Price
- Increased Margin Financing
- Recent Market Sentiment
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information